MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
1) Consolidators: Life Science & Therapeutics Sector
*Consolidators: Life Science Sector
Consolidators: BioPharmaceuticals
Sanofi-Aventis SA (NYSE: SNY)
Finance & Acquisitions: Sanofi
Inhibrx, Inc.
Organization & Developments: Inhibrx
Parents
Inhibrx, Inc.
Children
*Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi
*Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases.
*Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform.
2023: Inhibrx: Overlooked For More Selective Opportunities (Technical Analysis)_seekingalpha.com
2024: Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform_ seekingalpha.com
2024: Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation
2024: Sanofi inks $1.7B Inhibrx buyout, snagging rare disease drug but spinning out cancer programs
Jumps
Finance & Acquisitions: Inhibrx
Key People: Inhibrx